Review: taking Zantac 150 and Gaviscon together


Summary

Drug interactions are reported among people who take Zantac 150 and Gaviscon together. This review analyzes the effectiveness and drug interactions between Zantac 150 and Gaviscon. It is created by eHealthMe based on reports of 702 people who take the same drugs from FDA and social media, and is updated regularly.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Zantac 150

Zantac 150 has active ingredients of ranitidine hydrochloride. It is often used in indigestion. (latest outcomes from Zantac 150 4,243 users)

Gaviscon

Gaviscon has active ingredients of aluminum hydroxide; magnesium trisilicate. It is often used in gastrooesophageal reflux disease. (latest outcomes from Gaviscon 5,531 users)

On Sep, 18, 2016

702 people who take Zantac 150, Gaviscon are studied.


Number of reports submitted per year:

Zantac 150 and Gaviscon drug interactions.

Drug effectiveness over time:

Zantac 150:
  • < 1 month: 50.0% - (1 of 2 people)
  • 1 - 6 months: 100.0% - (2 of 2 people)
  • 6 - 12 months: 0.0% - (0 of 1 people)
  • 1 - 2 years: 0.0% - (0 of 1 people)
  • 2 - 5 years: 33.0% - (1 of 3 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Gaviscon:
  • < 1 month: 33.0% - (1 of 3 people)
  • 1 - 6 months: 0.0% - (0 of 1 people)
  • 6 - 12 months: 0.0% - (0 of 1 people)
  • 1 - 2 years: 0.0% - (0 of 1 people)
  • 2 - 5 years: 0.0% - (0 of 1 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 1 people)

Drug effectiveness by gender:

Zantac 150:
  • female: 50.0% - (3 of 6 people)
  • male: 33.0% - (1 of 3 people)
Gaviscon:
  • female: 0.0% - (0 of 5 people)
  • male: 33.0% - (1 of 3 people)

Drug effectiveness by age:

Zantac 150:
  • 0-1: 100.0% - (1 of 1 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 100.0% - (1 of 1 people)
  • 30-39: 33.0% - (1 of 3 people)
  • 40-49: 0.0% - (0 of 1 people)
  • 50-59: 0.0% - (0 of 2 people)
  • 60+: 100.0% - (1 of 1 people)
Gaviscon:
  • 0-1: 0.0% - (0 of 1 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 0.0% - (0 of 0 people)
  • 20-29: 0.0% - (0 of 1 people)
  • 30-39: 33.0% - (1 of 3 people)
  • 40-49: 0.0% - (0 of 0 people)
  • 50-59: 0.0% - (0 of 2 people)
  • 60+: 0.0% - (0 of 1 people)

Most common drug interactions over time *:

< 1 month:
  • muscle twitching
  • screaming
  • eye movement disorder
  • urosepsis
  • thrombocytopenia
  • renal impairment
  • drug ineffective
  • dyspnoea
  • electrocardiogram qt prolonged
  • heart rate irregular
1 - 6 months:
  • hypersensitivity
  • throat tightness
  • pulmonary embolism
  • back pain aggravated
  • drug eruption
  • dyspnoea
  • foetal exposure during pregnancy
  • gastric perforation
  • increased appetite
  • insomnia
6 - 12 months:
  • carpal tunnel syndrome
  • intervertebral disc protrusion
  • multiple fractures
  • osteoporosis
  • abdominal pain upper
  • anxiety
  • blood sodium decreased
  • choking
  • dyspnoea
  • loss of consciousness
1 - 2 years:
  • aggression
  • depressed mood
  • irritability
  • personality change
  • non-cardiac chest pain
  • pleurisy
2 - 5 years:
  • osteoporosis
  • carpal tunnel syndrome
  • intervertebral disc protrusion
  • multiple fractures
  • bone disorder
  • cataract
  • chronic obstructive pulmonary disease
  • depression
  • dyspnoea
  • fall
5 - 10 years:
  • bone disorder
  • cardiovascular disorder
  • cataract
  • cerebrovascular accident
  • depression
  • dyskinesia
  • dystrophic calcification
  • fall
  • femur fracture
  • foot fracture
not specified:
  • depression
  • osteoporosis
  • nausea
  • dyspnoea
  • vomiting
  • drug ineffective
  • diarrhoea
  • fall
  • pain
  • dyspepsia

Most common drug interactions by gender *:

female:
  • depression
  • nausea
  • osteoporosis
  • dyspnoea
  • vomiting
  • dyspepsia
  • drug ineffective
  • fall
  • fatigue
  • asthenia
male:
  • osteoporosis
  • pain
  • depression
  • diarrhoea
  • dyspnoea
  • drug ineffective
  • fall
  • malaise
  • vomiting
  • gastrooesophageal reflux disease

Most common drug interactions by age *:

0-1:
  • bradypnoea
  • malaise
  • muscle twitching
  • screaming
  • apnoea
  • cyanosis
  • respiratory disorder
  • abdominal pain upper
  • constipation
  • eye movement disorder
2-9:
  • febrile neutropenia
  • pancreatitis
  • splenomegaly
  • abdominal distension
  • blood calcium increased
  • blood phosphorus increased
  • epilepsy aggravated
  • face oedema
  • fanconi syndrome
  • hydronephrosis
10-19:
  • multi-organ failure
  • acute monocytic leukaemia
  • myeloid leukaemia
  • septic shock
  • transfusion reaction
  • hypotension
  • pruritus
  • back pain
  • vomiting
  • haemoglobin decreased
20-29:
  • asthenia
  • dyspepsia
  • abdominal distension
  • dyspnoea
  • dyspnoea exertional
  • eructation
  • insomnia
  • viral infection
  • vomiting
  • alveolitis
30-39:
  • pain
  • gastrooesophageal reflux disease
  • drug-induced liver injury
  • abdominal discomfort
  • anxiety
  • asthma
  • blood potassium decreased
  • chest discomfort
  • drug ineffective
  • dysphonia
40-49:
  • depression
  • osteoporosis
  • electrocardiogram qt prolonged
  • musculoskeletal discomfort
  • asthma
  • cognitive disorder
  • conversion disorder
  • injury
  • memory impairment
  • somnolence
50-59:
  • depression
  • osteoporosis
  • anxiety
  • arthritis
  • bone disorder
  • multiple fractures
  • vomiting
  • dyspepsia
  • nausea
  • fall
60+:
  • nausea
  • dyspnoea
  • diarrhoea
  • depression
  • drug ineffective
  • anaemia
  • fall
  • chest pain
  • vomiting
  • osteoporosis

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Zantac 150 and Gaviscon?

Can you answer these questions?

More questions for: Zantac 150, Gaviscon

You may be interested in these reviews

More reviews for: Zantac 150, Gaviscon

On eHealthMe, Zantac 150 (ranitidine hydrochloride) is often used to treat indigestion. Gaviscon (aluminum hydroxide; magnesium trisilicate) is often used to treat gastrooesophageal reflux disease. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.